| Autor: |
Jesse M. Tettero, Waleed K. W. Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Catharina H. M. J. van Elssen, Thomas Fischer, Bjorn T. Gjertsen, Gwendolyn N. Y. van Gorkom, Patrycja Gradowska, Marjolein J. E. Greuter, Laimonas Griskevicius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Bob Löwenberg, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Jacqueline Cloos |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 12 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2022.999822 |
| Popis: |
Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
